Page 1 | Search Results | Diabetes Care | American Diabetes Association

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Pathogenic, Total Loss-of-Function DYRK1B Variants Cause Monogenic Obesity Associated With Type 2 Diabetes

Lise Folon, Morgane Baron, Victoria Scherrer, Bénédicte Toussaint, Emmanuel Vaillant, Hélène Loiselle, Aurélie Dechaume, Frédérique De Pooter, Raphaël Boutry, Mathilde Boissel, Aboubacar Diallo, Lijiao Ning, Beverley Balkau, Guillaume Charpentier, Sylvia Franc, Michel Marre, Mehdi Derhourhi, Philippe Froguel, Amélie Bonnefond

Diabetes Care 2024;47(3):444–451

https://doi.org/10.2337/dc23-1851

Published: 03 January 2024

View articletitled, Pathogenic, Total Loss-of-Function DYRK1B Variants Cause Monogenic Obesity Associated With Type 2 Diabetes

Journal Articles

Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up

Coralie Amadou, Sylvia Franc, Pierre-Yves Benhamou, Sandrine Lablanche, Erik Huneker, Guillaume Charpentier, Alfred Penfornis

Diabetes Care 2021;44(3):844–846

https://doi.org/10.2337/dc20-1809

Published: 11 January 2021

View articletitled, Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up

Journal Articles

Comment on Leelarathna et al. Duration of Hybrid Closed-Loop Insulin Therapy to Achieve Representative Glycemic Outcomes in Adults With Type 1 Diabetes. Diabetes Care 2020;43:e38–e39

Pierre Yves Benhamou, Stéphanie Madrolle, Sandrine Lablanche, Alexandre Gallegos, Yousra Tourki, Sylvia Franc, Maeva Doron, Guillaume Charpentier

Diabetes Care 2020;43(10):e167

https://doi.org/10.2337/dc20-1291

Published: 11 September 2020

View articletitled, Comment on Leelarathna et al. Duration of Hybrid Closed-Loop Insulin Therapy to Achieve Representative Glycemic Outcomes in Adults With Type 1 Diabetes. Diabetes Care 2020;43:e38–e39

Journal Articles

The Diabeo Software Enabling Individualized Insulin Dose Adjustments Combined With Telemedicine Support Improves HbA_1c in Poorly Controlled Type 1 Diabetic Patients: A 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 Study)

Guillaume Charpentier, MD, Pierre-Yves Benhamou, MD, Dured Dardari, MD, Annie Clergeot, MD, Sylvia Franc, MD, Pauline Schaepelynck-Belicar, MD, Bogdan Catargi, MD, Vincent Melki, MD, Lucy Chaillous, MD, Anne Farret, MD, Jean-Luc Bosson, MD, Alfred Penfornis, MD, on behalf of the TeleDiab Study Group

Diabetes Care 2011;34(3):533–539

https://doi.org/10.2337/dc10-1259

Published: 17 February 2011

View articletitled, The Diabeo Software Enabling Individualized Insulin Dose Adjustments Combined With Telemedicine Support Improves HbA1c in Poorly Controlled Type 1 Diabetic Patients: A 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 Study)

Includes: Supplementary data

Journal Articles

Can Postprandial Blood Glucose Excursion Be Predicted in Type 2 Diabetes?

Sylvia Franc, MD, Dured Dardari, MD, Caroline Peschard, MSC, Jean-Pierre Riveline, MD, Magdalena Biedzinski, MD, Beatrix Boucherie, MD, Catherine Petit, MD, Elisabeth Requeda, MD, Frederic Mistretta, MSC, Michel Varroud-Vial, MD, Guillaume Charpentier, MD

Diabetes Care 2010;33(9):1913–1918

https://doi.org/10.2337/dc10-0115

Published: 14 June 2010

View articletitled, Can Postprandial Blood Glucose Excursion Be Predicted in Type 2 Diabetes?

Update search

NARROW

Format

Journal

Article Type

Topics

Subjects

Issue Section

Date

Availability

Pathogenic, Total Loss-of-Function DYRK1B Variants Cause Monogenic Obesity Associated With Type 2 Diabetes

Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up

Comment on Leelarathna et al. Duration of Hybrid Closed-Loop Insulin Therapy to Achieve Representative Glycemic Outcomes in Adults With Type 1 Diabetes. Diabetes Care 2020;43:e38–e39

The Diabeo Software Enabling Individualized Insulin Dose Adjustments Combined With Telemedicine Support Improves HbA_1c in Poorly Controlled Type 1 Diabetic Patients: A 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 Study)

Can Postprandial Blood Glucose Excursion Be Predicted in Type 2 Diabetes?

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Update search

Pathogenic, Total Loss-of-Function DYRK1B Variants Cause Monogenic Obesity Associated With Type 2 Diabetes

Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up

Comment on Leelarathna et al. Duration of Hybrid Closed-Loop Insulin Therapy to Achieve Representative Glycemic Outcomes in Adults With Type 1 Diabetes. Diabetes Care 2020;43:e38–e39

The Diabeo Software Enabling Individualized Insulin Dose Adjustments Combined With Telemedicine Support Improves HbA1c in Poorly Controlled Type 1 Diabetic Patients: A 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 Study)

Can Postprandial Blood Glucose Excursion Be Predicted in Type 2 Diabetes?

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only

The Diabeo Software Enabling Individualized Insulin Dose Adjustments Combined With Telemedicine Support Improves HbA_1c in Poorly Controlled Type 1 Diabetic Patients: A 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 Study)